JP2022506613A - 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用 - Google Patents

内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用 Download PDF

Info

Publication number
JP2022506613A
JP2022506613A JP2021524060A JP2021524060A JP2022506613A JP 2022506613 A JP2022506613 A JP 2022506613A JP 2021524060 A JP2021524060 A JP 2021524060A JP 2021524060 A JP2021524060 A JP 2021524060A JP 2022506613 A JP2022506613 A JP 2022506613A
Authority
JP
Japan
Prior art keywords
amino acid
acid substitutions
amino acids
sequence
target protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524060A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020097372A5 (https=
JP2022506613A5 (https=
Inventor
エマニュエル ジェイ． サイモンズ，
ロバート ング，
ダニエル レンズ，
ミシェル バレロ，
Original Assignee
アコーオス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アコーオス インコーポレイテッド filed Critical アコーオス インコーポレイテッド
Publication of JP2022506613A publication Critical patent/JP2022506613A/ja
Publication of JPWO2020097372A5 publication Critical patent/JPWO2020097372A5/ja
Publication of JP2022506613A5 publication Critical patent/JP2022506613A5/ja
Priority to JP2024048210A priority Critical patent/JP2024086735A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021524060A 2018-11-07 2019-11-07 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用 Pending JP2022506613A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024048210A JP2024086735A (ja) 2018-11-07 2024-03-25 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862756953P 2018-11-07 2018-11-07
US62/756,953 2018-11-07
US201962888093P 2019-08-16 2019-08-16
US62/888,093 2019-08-16
PCT/US2019/060328 WO2020097372A1 (en) 2018-11-07 2019-11-07 Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024048210A Division JP2024086735A (ja) 2018-11-07 2024-03-25 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用

Publications (3)

Publication Number Publication Date
JP2022506613A true JP2022506613A (ja) 2022-01-17
JPWO2020097372A5 JPWO2020097372A5 (https=) 2023-07-07
JP2022506613A5 JP2022506613A5 (https=) 2023-07-07

Family

ID=70611216

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524060A Pending JP2022506613A (ja) 2018-11-07 2019-11-07 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用
JP2024048210A Pending JP2024086735A (ja) 2018-11-07 2024-03-25 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024048210A Pending JP2024086735A (ja) 2018-11-07 2024-03-25 内耳の有毛細胞及び支持細胞における遺伝子欠陥／発現タンパク質を修正するためのアデノ随伴ウイルスベクターの使用

Country Status (7)

Country Link
US (2) US20230056182A1 (https=)
EP (2) EP4063510A1 (https=)
JP (2) JP2022506613A (https=)
CN (2) CN118497276A (https=)
AU (1) AU2019377115A1 (https=)
CA (1) CA3119065A1 (https=)
WO (1) WO2020097372A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019530737A (ja) 2016-08-23 2019-10-24 アコーオス インコーポレイテッド ヒト対象において非加齢性聴力障害を治療するための組成物および方法
MX2020006435A (es) 2017-12-19 2021-02-09 Akouos Inc Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno.
US12054724B2 (en) 2018-04-10 2024-08-06 President And Fellows Of Harvard College AAV vectors encoding clarin-1 or GJB2 and uses thereof
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN119410636A (zh) 2018-04-27 2025-02-11 分贝治疗公司 肌球蛋白15启动子及其用途
AU2020218547A1 (en) 2019-02-08 2021-08-26 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
CA3159549A1 (en) 2019-10-30 2021-05-06 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
JP7807380B2 (ja) 2020-02-21 2026-01-27 アコーオス インコーポレイテッド ヒト対象において非加齢関連聴力障害を処置するための組成物および方法
EP4164695A4 (en) * 2020-05-13 2024-06-05 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS
US20240016955A1 (en) * 2020-09-14 2024-01-18 President And Fellows Of Harvard College Dual-aav vector delivery of pcdh15 and uses thereof
JP2023541443A (ja) * 2020-09-14 2023-10-02 プレジデント アンド フェローズ オブ ハーバード カレッジ ＧＪＢ２をコードする組換えアデノ随伴ウイルス（ｒＡＡＶ）およびその使用。
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
AU2021376225A1 (en) * 2020-11-06 2023-06-22 Eli Lilly And Company Variant adeno-associated virus (aav)capsid polypeptides and gene therapeutics thereof for treatment of hearing loss
IL303317A (en) * 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
MX2023007800A (es) 2020-12-29 2023-07-11 Akouos Inc Composiciones y metodos para tratar la perdida de audicion y/o la perdida de vision asociada a clrn1.
US20220267795A1 (en) * 2021-02-24 2022-08-25 Kinase Pharma Inc. Compositions and methods for regulating production of an angiogensis inhibitor
EP4473011A1 (en) * 2022-02-02 2024-12-11 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
KR20250080886A (ko) * 2022-09-30 2025-06-05 데시벨 테라퓨틱스, 인크. Slc26a4 조절 요소 및 이의 용도
WO2025179016A1 (en) * 2024-02-20 2025-08-28 Skylark Bio, Inc. Recombinant adeno associated virus and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501819A (ja) * 1996-09-25 2001-02-13 セル・ジェネシス・インコーポレイテッド アデノ随伴ウィルスベクターの非侵襲性投与
JP2002516345A (ja) * 1998-05-27 2002-06-04 セル ジェネシス インコーポレイテッド 第ｖｉｉｉ因子活性のアデノ随伴ウイルスベクター媒介性発現
JP2016501023A (ja) * 2012-12-04 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭ 条件付き複製ウイルスベクター
WO2017100791A1 (en) * 2015-12-11 2017-06-15 Massachusetts Eye And Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075838A1 (en) * 2009-12-21 2011-06-30 Audigen Inc. Method of treating or preventing hearing loss
CA2909733C (en) * 2013-04-18 2023-10-17 Fondazione Telethon Effective delivery of large genes by dual aav vectors
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
TWI813532B (zh) * 2015-06-18 2023-09-01 美商博得學院股份有限公司 降低脱靶效應的ｃｒｉｓｐｒ酶突變
WO2017136764A1 (en) * 2016-02-05 2017-08-10 The General Hospital Corporation Hybrid system for efficient gene delivery to cells of the inner ear
WO2017181021A1 (en) * 2016-04-15 2017-10-19 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
JP2019530737A (ja) * 2016-08-23 2019-10-24 アコーオス インコーポレイテッド ヒト対象において非加齢性聴力障害を治療するための組成物および方法
KR102746901B1 (ko) * 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501819A (ja) * 1996-09-25 2001-02-13 セル・ジェネシス・インコーポレイテッド アデノ随伴ウィルスベクターの非侵襲性投与
JP2002516345A (ja) * 1998-05-27 2002-06-04 セル ジェネシス インコーポレイテッド 第ｖｉｉｉ因子活性のアデノ随伴ウイルスベクター媒介性発現
JP2016501023A (ja) * 2012-12-04 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭ 条件付き複製ウイルスベクター
WO2017100791A1 (en) * 2015-12-11 2017-06-15 Massachusetts Eye And Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INVEST OPHTHALMOL VIS SCI., vol. 59, JPN6023039456, October 2018 (2018-10-01), pages 4909 - 4920, ISSN: 0005327310 *
MOL THER METHODS CLIN DEV., vol. 11, JPN6023039455, 4 September 2018 (2018-09-04), pages 29 - 39, ISSN: 0005327309 *
実験医学, vol. 12, no. 15, JPN6023039457, 1994, pages 41 - 46, ISSN: 0005327311 *

Also Published As

Publication number Publication date
WO2020097372A8 (en) 2021-04-29
US20230056182A1 (en) 2023-02-23
US20250041457A1 (en) 2025-02-06
EP4063510A1 (en) 2022-09-28
JP2024086735A (ja) 2024-06-28
CN113853437A (zh) 2021-12-28
EP3880826A1 (en) 2021-09-22
AU2019377115A1 (en) 2021-05-20
EP3880826A4 (en) 2022-08-24
CN118497276A (zh) 2024-08-16
CA3119065A1 (en) 2020-05-14
WO2020097372A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
US20250041457A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
AU2018223041B2 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
AU2017315679B2 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
AU2016364667A1 (en) Materials and methods for treatment of Alpha-1 antitrypsin deficiency
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
KR20220012230A (ko) 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물
KR20220024184A (ko) 대장암의 검출
CA2936612A1 (en) Atf6 polymorphisms associated with myocardial infarction, method of detection and uses thereof
AU2016351889A1 (en) Detection of foetal chromosomal aneuploidies using DNA regions that are differentially methylated between the foetus and the pregnant female
KR20170086027A (ko) 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
KR20220025749A (ko) 대장암의 검출
KR102777514B1 (ko) 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
KR20110110030A (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
CN101151371B (zh) 治疗中的逆转录转座子抑制
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
TW202227102A (zh) 治療脂肪肝病之方法
CN100516876C (zh) 用于诊断肾细胞癌(rcc)和其他实体瘤的方法
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
WO2018209358A2 (en) Systemic delivery of polypeptides
KR102477906B1 (ko) 유도만능 줄기세포 분화 특이적 lncRNA, 및 이의 용도
KR102364720B1 (ko) 교모세포종 진단용 바이오마커 조성물
JP2003259875A (ja) ヒト遺伝子の一塩基多型（４）
KR20150094601A (ko) 성별에 독립적인 연령 결정 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230925

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521